This announcement is a separate document:
サンバイオ：国内SB623慢性期外傷性脳損傷プログラム製造販売承認取得の状況について（続報)
SanBio: Status update on the manufacturing approval for the domestic SB623 chronic traumatic brain injury program (continuation report).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.